ANTARES PHARMA INC's ticker is ATRS and the CUSIP is 036642106. A total of 161 filers reported holding ANTARES PHARMA INC in Q4 2019. The put-call ratio across all filers is 5.95 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $272,000 | -72.3% | 66,276 | -75.9% | 0.01% | -73.9% |
| Q4 2021 | $982,000 | +55.4% | 275,025 | +58.3% | 0.02% | +35.3% |
| Q3 2021 | $632,000 | +80.1% | 173,710 | +116.0% | 0.02% | +54.5% |
| Q2 2021 | $351,000 | +147.2% | 80,422 | +133.5% | 0.01% | +120.0% |
| Q1 2021 | $142,000 | -38.5% | 34,439 | -40.5% | 0.01% | -44.4% |
| Q4 2020 | $231,000 | +291.5% | 57,914 | +166.3% | 0.01% | +125.0% |
| Q3 2020 | $59,000 | +90.3% | 21,746 | +93.4% | 0.00% | +100.0% |
| Q2 2020 | $31,000 | -65.6% | 11,242 | -70.4% | 0.00% | -71.4% |
| Q1 2020 | $90,000 | -95.2% | 37,998 | -93.2% | 0.01% | -95.9% |
| Q3 2019 | $1,865,000 | +41.7% | 557,477 | +39.3% | 0.17% | +42.5% |
| Q2 2019 | $1,316,000 | +171.9% | 400,062 | +150.4% | 0.12% | +155.3% |
| Q1 2019 | $484,000 | +1110.0% | 159,782 | +919.3% | 0.05% | +1466.7% |
| Q2 2018 | $40,000 | +66.7% | 15,676 | +29.4% | 0.00% | -25.0% |
| Q4 2017 | $24,000 | – | 12,110 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JW Asset Management, LLC | 1,671,956 | $5,384,000 | 3.43% |
| ARMISTICE CAPITAL, LLC | 5,700,000 | $18,354,000 | 2.34% |
| Rubric Capital Management LP | 3,188,600 | $10,267,000 | 2.12% |
| Broadfin Capital, LLC | 4,803,528 | $15,467,000 | 1.88% |
| THOMPSON DAVIS & CO., INC. | 192,734 | $621,000 | 1.00% |
| Asymmetry Capital Management, L.P. | 199,655 | $643,000 | 0.76% |
| Perceptive Advisors | 4,267,253 | $13,741,000 | 0.69% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 946,987 | $3,049,000 | 0.21% |
| Brown Advisory Securities, LLC | 275,000 | $886,000 | 0.20% |
| EAM Investors, LLC | 251,619 | $810,000 | 0.13% |